Table 3.

Associations between VEGF haplotype and breast cancer risk

Haplotype*All subjects (%)
Premenopause
Postmenopause
Cases (%)Controls (%)OR (95% CI)Cases (%)Controls (%)OR (95% CI)Cases (%)Controls (%)OR (95% CI)
T-C-C34.133.61.00 (reference)33.331.61.00 (reference)35.236.71.00 (reference)
T-G-C29.629.80.97 (0.84-1.11)30.429.90.96 (0.80-1.14)28.429.80.97 (0.77-1.24)
C-G-C17.717.01.02 (0.86-1.21)18.717.81.01 (0.82-1.25)15.715.71.01 (0.75-1.36)
C-G-T8.28.40.96 (0.78-1.18)7.08.60.80 (0.61-1.03)10.37.51.37 (0.97-1.95)
T-C-T5.96.00.98 (0.76-1.25)6.06.30.96 (0.71-1.31)5.65.80.96 (0.63-1.48)
T-G-T3.94.60.67 (0.43-1.04)3.95.00.47 (0.27-0.81)3.73.71.07 (0.65-3.16)
  • Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.

  • * In the order of T−460C, C+405G, and C936T. Haplotype frequency was derived using the program PHASE.